Vascular invasion is not a risk factor in oesophageal cancer recurrence  by Waraich, N. et al.
lable at ScienceDirect
International Journal of Surgery 9 (2011) 237e240
ORIGINAL RESEARCHContents lists avaiInternational Journal of Surgery
journal homepage: www.thei js .comOriginal Research
Vascular invasion is not a risk factor in oesophageal cancer recurrenceq
N. Waraich a, F. Rashid a,*, A. Jan a, D. Semararo b, R. Deb c, P.C. Leeder a, S.Y. Iftikhar a
aDepartment of Surgery, Royal Derby Hospital, Derby, DE223NE, UK
bDepartment of Pathology, Royal Derby Hospital, Derby, DE223NE, UK
cDepartment of Oncology, Royal Derby Hospital, Derby, DE223NE, UKa r t i c l e i n f o
Article history:
Received 26 August 2010
Accepted 1 December 2010
Available online 15 December 2010
Keywords:
Vascular invasion
Oesophageal cancerq This paper was presented at Association of su
Ireland 2008.
* Corresponding author. Division of GI Surgery, Sch
cine and Health, University of Nottingham, Royal De
Derby DE223DT, UK. Tel.: þ44 1332724702 (Ofﬁce)
fax: þ44 1332787878.
E-mail address: farhan.rashid@nottingham.ac.uk (
1743-9191/$ e see front matter  2010 Surgical Asso
doi:10.1016/j.ijsu.2010.12.002a b s t r a c t
Aim: The outcome of the treatment of oesophageal cancer remains poor despite improved treatment
modalities and recurrence remains a major problem despite improved staging and treatment. The aim
was to identify the independent risk factors responsible in the recurrence of oesophageal cancer.
Methods: The patients who had elective oesophagectomy (n ¼ 244) with curative intent were studied.
One hundred and eighty four patients had surgery alone, 44 patients had neo-adjuvant chemotherapy
and surgery while 16 patients had neo-adjuvant chemotherapy, surgery and adjuvant chemotherapy. We
have analyzed patients who had surgery alone (n ¼ 184). Data was collected for demography, type of
operation, histology, staging (TNM), vascular invasion (VI), differentiation of tumour, type of chemo-
therapy and recurrence of tumour.
Results: The median age was 67 years (IQR 60, 71). The T1, T2, T3 distribution was 10%, 24% and 66%
respectively. Forty percent had no nodal involvement (N0) and 60% had N1 stage disease. Twenty three
percent of patients had vascular invasion. Univariate analysis of histo-pathological factors identiﬁed
lymph node yield (p ¼ 0.06), curative resection R0 (p ¼ 0.004) and vascular invasion (VI) (P ¼ 0.69) as
prognostic indicators of recurrence. Multivariate analysis showed that number of lymph nodes yielded
(p ¼ 0.01) and R0 resection remain independent indicators of recurrence of tumour. However, VI (p ¼ 0.2)
and age at disease onset (p ¼ 0.8) were not indicators of recurrence in oesophageal cancer patients.
Conclusion: R0 and lymph node yield may help to predict the recurrence of oesophageal cancer. However
the presence of VI may not be a signiﬁcant risk factor in disease recurrence.
 2010 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Introduction
Oesophageal cancer is currently the ﬁfth most common cause of
cancer related death in the world.1,2 The prognosis of both oeso-
phageal squamous carcinoma and adenocarcinoma is dismal, with
frequent metastasis and low survival rate despite improved mul-
timodality treatment.3,4
Themainstay of treatment remains surgical resection,with some
improvement in outcome in recent years.5 Grifﬁn et al. highlighted
the importance of availability of facilities, expertise, careful patient
selection and execution of surgery, in order to reduce morbidity,
mortality and improve survival outcome. However, recent advances
have failed to translate into a substantial improvement in long-termrgeons of Great Britain and
ool of Graduate Entry Medi-
rby Hospital, Uttoxeter Road,
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F. Rashid).
ciates Ltd. Published by Elsevier Ltsurvival after surgical resection with 5-year survival rates rarely
exceeding 30%. This poses real challenges to improve the outcomeof
treatment in oesophageal cancer and need for alternative manage-
ment strategies.5e9
Early tumour recurrence remains a signiﬁcant problem. Clark
et al. have reported nodal and systemic recurrence rates of 39.5%.
Local anastomotic recurrencewas 10.5%withmean follow-upof 16.5
months.10 Prognosis following recurrence remains extremely poor,
with fewexceptions. Isono et al. reported themedian survival period
after recurrence to be eightmonths after nodal, and fourmonths for
other types of recurrence. The survival period was reported as even
worse, at only two months after peritoneal recurrence.11
Lymph node involvement in oesophageal carcinoma is identiﬁed
as an independent factor inﬂuencing both disease recurrence and
survival.12,13 The high frequency of recurrence and poor survival
emphasise the need for additional, effective peri-operative treat-
ment. The failure of current adjuvant therapy to signiﬁcantly
improve the prognosis of patients undergoing esophago-gastrec-
tomy for cancer may be either because of poor patient selection or
other patho-physiological factors.14,15d. All rights reserved.
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the literature. These include delayed clinical presentation, or the
presence of micro metastases spreading via longitudinal lymphatic
drainage within the submucosal plexus at time of resection.16 The
theory of micro metastasis is further supported by O’Sullivan et al.
who identiﬁed the presence of rib marrow metastasis in patients
undergoing curative resection of oesophago-gastric malignancies.17
Local and regional metastases often occur within one year of
surgery, indicating that both must have been present at the time of
operation. Distant metastases probably require more time to
develop. This raises the concept of local and regional factors which
inﬂuence the impact of disease. The prognostic factors identiﬁed by
univariate analysis in different series are tumour size, depth of
invasion, lymph node invasion, intra mural metastasis, lymphatic
invasion and vascular invasion (Fig. 1).18e20 T-Stage, N-Stage and
Grade of disease are already established key variables in the
development of both locoregional and distant metastatic recur-
rence. However, the role of vascular invasion remains ill deﬁned
and therefore warrants further investigation.
2. Material and methods
2.1. Patients
All patients who underwent curative oesophageal resection for cancer of the
oesophagus at Derby Upper GI cancer centre between 1995 and 2005 were included
in the study. A dedicated team of surgeons, anaesthetists and pathologists managed
all the patients. All cases were discussed preoperatively and post-operatively in
a multidisciplinary team (MDT) meeting to determine the optimal treatment for
each individual patient. All patients underwent oesophago-gastro-duodenoscopy
(OGD), computed tomography (CT), endoluminal ultrasound (EUS), staging lapa-
roscopy, echocardiogram and pulmonary function test (PFT), with gas exchange in
selected cases prior to the surgical resection.
2.1.1. Inclusion criteria
a. Patients with operable cancer of the oesophagus
b. Patients with gastro-oesophageal junction (GOJ) cancer, Siewert IeIII
c. Patients who underwent elective potentially curative resection2.1.2. Exclusion criteria
a. Patients who had ﬁxed unresectable tumour per-operatively
b. Patients who had Neo-Adjuvant chemotherapy
c. Patients who had Adjuvant Chemotherapy
d. Patients underwent oesophagectomy for non-cancer disease.2.1.3. Surgical approach
Siewert type IeIII oesophago-gastric cancers were resected via a single stage
left thoracotomy and phrenotomy. The remainder of cancers were resected via anFig. 1. Vascular invasion of tumour.IvoreLewis two stage approach. All the patients had a standard two level lymph
node clearance.
2.2. Data collection
Datawas collected for age, gender, type of operation, histology type, lymph node
yield, vascular invasion, differentiation of tumour, stage (TNM), type of chemo-
therapy, recurrence of tumour, date of operation and date of death (where
applicable).
All the information was identiﬁed from hospital case notes and theatre records.
Patient follow-up and date of death was determined from the hospital notes and
patient administrative system (PAS).
2.3. Histology
In the initial phase, pathology specimens were analyzed by a non-dedicated
pathologist, however after 2002 a dedicated teamof upper GI pathologists examined
all resection specimens. Specimen analysis was performed in a standardized fashion
and the histological stage of tumour was classiﬁed according to TNM criteria for
oesophageal cancer established by the International Union against Cancer/American
Joint committee on cancer21 (Table 1). The pathologist identiﬁed all removed lymph
nodes according to their location (coeliac axis, left gastric artery, lesser gastric
curvature, left and right paracardial, para-oesophageal and subcarinal). Further-
more Barrett’s metaplasia, lymphatic invasion, vascular invasion, the total number of
lymph nodes retrieved and the presences of lymph nodes with tumour invasion
were recorded.
2.4. Recurrence
Local, regional, transcoelomic (pleural or peritoneal) and distant (haematoge-
nous) metastases were considered as manifestations of recurrence of disease.
Recurrence at cervical, coeliac, mediastinal and para aortic lymph nodes was clas-
siﬁed as locoregional recurrence. Disease recurrence was diagnosed on clinical
grounds, identiﬁed on OGD or CT depending on the symptomatic presentation of the
post-operative patient.
2.5. Follow-up
All patients were seen at the outpatient clinic at three monthly intervals for the
ﬁrst year and then every 6 months thereafter for ﬁve years. After ﬁve years, annual
follow-up has been carried out on all surviving patients. Radiological modalities,
haematological and endoscopic interventions were not used routinely during
follow-up. However when recurrence was suspected, additional investigations were
performed when clinically indicated.
2.6. Statistical analysis
Statistical package for social science (SPSS) version 15.0 was used to perform
statistical analyses of the available data. Time to event was measured from the date
of ﬁrst deﬁnitive treatment (surgical) to the date of recorded death. Any cause of
death was recorded as an event, which may have been directly related or unrelated
to disease progression or relapse.
Mean and median values were compared by statistical analysis. Death within 30
days of surgical resection and time of survival were used as endpoints for assessing
post-operative death and prognostic factors. Survival probabilities were calculated
using the KaplaneMeier method and difference in survival was assessed by the
log rank test. A multivariate Cox regression analysis was performed to assessTable 1
Clinical characteristics of 184 patients submitted to potentially curative resection for
oesophageal cancer.
Variables Number of patients
Gender M/F 146/38
Age 67 (60.71)
Histology
Adenocarcinoma 146 (79.3%)
Squamous 38 (20.7%)
Well differentiated 22 (12%)
Moderately differentiated 67 (36%)
Poorly differentiated 95 (52%)
pTi/pT2/pT3 18/44/122 (10%, 24%, 66%)
pN0/pN1 73/111 (40%, 60%)
Vascular invasion 41 (22.2%)
R0 129 (70%)
Recurrence 70 (38%)
N. Waraich et al. / International Journal of Surgery 9 (2011) 237e240 239
ORIGINAL RESEARCHindependent predictors of prognosis following curative resection. A p value of less
than 0.05 was considered to be statistically signiﬁcant.
3. Results
Our cohort included 244 patients who had curative elective
oesophagectomy at Derby upper GI cancer centre between 1995
until 2005.
Out of 244 patients 184 had surgery alone while 44 patients had
preoperative chemotherapy followed by surgery and16 patients
had preoperative chemotherapy followed by surgery and subse-
quent post-operative chemotherapy. Therefore, 60 patients were
excluded from the study, in order to eliminate the effects of neo-
adjuvant and adjuvant chemotherapy on recurrence and over-all
patient survival.
The median age of study patients was 67 years (IQR 60e71) at
the time of surgical resectionwith a male to female ratio of 4:1. One
hundred and forty six patients had oesophageal adenocarcinoma
and 38 had squamous cell cancer.
T1, T2, and T3 stages were identiﬁed respectively, in 10%
(n ¼ 18), 24% (n ¼ 44) and 66% (n ¼ 122) of patients’ post-operative
histological staging.
Forty percent (n¼ 73) of patients had no nodal involvement and
60% (n ¼ 111) had N1 stage. The median lymph node yield was 11
(IQR 8, 20) and median number of positive lymph nodes was two
(IQR 0, 8).
Twenty-two patients (12%) had well differentiated oesophageal
carcinoma, 67 (36%) had moderately differentiated cancer and 95
(52%) had poorly differentiated tumour. One hundred and twenty-
nine patients (70%) had microscopically clear resection margins
(R0). Twenty three percent of patients (n ¼ 41) had vascular inva-
sion (Table 1).
Patients were followed up regularly every three months post
surgery. Thirty eight percent (n ¼ 70) of patients developed recur-
rence during the study period and more than half of these patients
n ¼ 40 had recurrence within one year of their surgery. Only three
patients (6%) with T1 disease had recurrence (p ¼ 0.61), 14 patients
(32%) with T2 disease developed (p ¼ 0.01) recurrence and 57
patients (47%) with T3 disease had disease recurrence (p ¼ 0.001).
Fifty percent of patients with N1 disease (n ¼ 55) showed
recurrence of disease and 28% of patients with N0 (n ¼ 21) disease
had recurrence following intentionally curative resection.
Univariate analysis of histo-pathological factors indicated that
lymph node yield (p¼ 0.06), curative resection (R0) (p¼ 0.004) and
vascular Invasion (VI) (P ¼ 0.69) were all prognostic indicators of
recurrence.
Multivariate analysis conﬁrmed total lymphnode yield (p¼ 0.01)
and R0 (0.003) resection to be independent indicators of disease
recurrence. However, vascular invasion (p ¼ 0.2) and age (P ¼ 0.8)
werenot the indicators of recurrence inoesophageal cancer patients.
4. Discussion
Despite comprehensive preoperative staging to carefully select
patients for potentially curative surgery for oesophageal cancer,
recurrence remains a problematic and frequent issue. Lymphatic and
haematogenous dissemination probably both occur in parallel. The
vast majority of the patients develop either locoregional disease or
distant metastases within two years after surgery. Early recurrence
indicates that many patients have unrecognised micro metastatic
disease at the time of surgery and present later with locoregional,
haematogenous, and/or transcelomic recurrences.18,21e25
Multiple pathological factors are known to play an important
role in the prognosis and ﬁnal outcome of patients with oesopha-
geal cancer, even after potentially curative resection of cancer.These factors included T-stage, N-stage, differentiation of tumour,
R0 (microscopic clearance) resection, and R1 (macroscopic clear-
ance) resection. However the role of vascular invasion in oeso-
phageal carcinoma remains unclear.
The important prognostic role of vascular invasion has been
widely discussed in the literature in thyroid, colorectal, hepato
pancreaticobilliary, breast and prostate cancer, as well as sarcoma.
Its exact role in oesophageal cancer is yet to be established. The
presence of vascular invasion has not been found to be a consistent
ﬁnding and to date has not been reported to be associated with an
increased incidence of lymph node or distant metastasis.26e30
The impact of tumour stage (T), lymph noted stage (N), curative
resection (RO) and vascular invasion have beenwidely discussed in
the context of survival from oesophageal cancer.12,13,31 However,
vascular invasion has not been assessed fully as a potential predictor
of tumour recurrence.
Multivariate analysis in our study identiﬁed lymph node yield to
be a signiﬁcant prognostic indicator of locoregional recurrence. Our
results are inconsistent with studies performed by Hulscher et al.
(cohort n ¼ 137) and Dressener et al. (Cohort n ¼ 176). However
both of these studies failed to describe the exclusion of patients
who had neo-adjuvant chemotherapy.
In our cohort of 184 patients, Univariate analysis of radicality of
resection (R0) showed a signiﬁcant (P ¼ 0.004) impact on over-all
recurrence of the disease following potentially curative resection.
Multivariate analysis conﬁrmed that R0 resection was an inde-
pendent prognostic indicator of tumour recurrence. The micro-
scopic clearance of disease following surgery is a good indicator of
over-all survival. However most of the previous studies have sparse
data, without clear exclusion criteria of patients who had neo-
adjuvant or adjuvant chemo-radiotherapy. The current cohort
included patients who underwent surgical resection only. This
excludes the potential bias in the study, as neo-adjuvant and
adjuvant chemotherapy are both known to inﬂuence recurrence
rates and potentially improve over-all survival. The Medical
Research Council (MRC) OE02 trial found a signiﬁcantly improved
survival following neo-adjuvant chemotherapy in oesophageal
cancer as compared to surgery alone.32 Preliminary results from the
Medical Research Council (MRC UK) Multi centre trial (MAGIC) of
patients with resectable adenocarcinoma of the stomach, gastro-
oesophageal junction and lower oesophagus has also suggested the
survival beneﬁts of neo-adjuvant chemotherapy.33
Over half of study patients with recurrent tumour had vascular
invasion. Neither univariate nor multivariate analysis identiﬁed
a signiﬁcant impact of vascular invasion on disease recurrence. The
present study is contrary to the study by Zaferillis et al. which
showed that vascular invasion was an independent prognostic
indicator; however, this study did not describe exclusion and
inclusion criteria which may have added potential bias. In a similar
study, Osugi et al. recruited patients with surgical resections only
and excluded the patients with neo-adjuvant chemotherapy.
Multivariate analysis in their study suggested that vascular invasion
seems to play no signiﬁcant role in the prognosis of oesophageal
cancer (p ¼ 0.65). The signiﬁcance of lymphatic invasionwas found
to be better than vascular invasion for generalized metastasis and
there was equal speciﬁcity for lymphatic invasion suggesting the
presence of micro metastasis at time of resection.31,34
Our ﬁndings conﬁrmed that the vascular invasion is not a signif-
icant indicator of recurrence of oesophageal cancer.
Porschen et al. studied the vascularization of both normal
oesophagus and carcinoma of the oesophagus. They demonstrated
less capillary volume, less total volume, less vascular surface area
and less vascular length in oesophageal cancer than the normal
oesophagus.35 The oesophagus is a tubular structure with compar-
atively more tenuous vascularity than other organs. It relies on
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arteries for its blood supply.36 A possible explanation of less vascular
invasion could be related to either the anatomy of oesophagus or
carcinogenesis of oesophageal malignancy. This may explain our
ﬁndings that vascular invasionmaynot playany role in recurrence as
compared to lymphatic invasion.
The retrospective nature of data has imposed some limits on
our study. Also introduction of dedicated pathologist may have
contributed towards improved median number of yielded lymph
nodes.5. Conclusion
Curative resection R0 and total lymph node yield may predict
the recurrence of oesophageal cancer. However, the presence of
vascular invasion has not been shown consistently to be an inde-
pendent pathological risk factor in the recurrence of oesophageal
malignancy.
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